Cargando…

Time to Regain Birthweight and Association with Neurodevelopmental Outcomes among Extremely Preterm Newborns

OBJECTIVE: Determine association between time to regain birthweight and 2-year neurodevelopment among extremely preterm (EP) newborns. STUDY DESIGN: Secondary analysis of the Preterm Erythropoietin Neuroprotection Trial evaluating time to regain birthweight, time from birth to weight nadir, time fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Valentine, Gregory, Perez, Krystle, Wood, Thomas, Mayock, Dennis, Law, Janessa, Kolnik, Sarah, Strobel, Katie, Brandon, Olivia, Comstock, Bryan, Heagerty, Patrick, Juul, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543289/
https://www.ncbi.nlm.nih.gov/pubmed/37790304
http://dx.doi.org/10.21203/rs.3.rs-3249598/v1
Descripción
Sumario:OBJECTIVE: Determine association between time to regain birthweight and 2-year neurodevelopment among extremely preterm (EP) newborns. STUDY DESIGN: Secondary analysis of the Preterm Erythropoietin Neuroprotection Trial evaluating time to regain birthweight, time from birth to weight nadir, time from nadir to regain birthweight, and cumulative weight loss with 2-year corrected Bayley Scales of Infant and Toddler Development 3rd edition. RESULTS: Among n = 654 EP neonates, those with shorter nadir-to-regain had lower cognitive scores (2–4 days versus ≥ 8 days: −3.5, [CI −7.0, 0.0]; ≤1 day versus ≥ 8 days: −5.0, [CI −10.2, 0.0]) in fully adjusted stepwise forward regression modeling. Increasingly cumulative weight loss was associated with lower cognitive scores (−50 to <−23 percent-days: −4.0, [95% CI −7.6, −0.4]) and language scores (≤−50 percent-days: −5.7, [CI −9.8, −1.6]; −50 to <−23 percent-days: −6.1, [CI −10.2, −2.0]). CONCLUSION: Faster nadir-to-regain and prolonged, severe weight loss are associated with adverse 2-year neurodevelopmental outcomes. TRIAL REGISTRATION: PENUT Trial Registration: NCT01378273. https://clinicaltrials.gov/ct2/show/NCT01378273